A phase II study on Mefatinib as first-line treatment of patients with advanced non-small-cell lung cancer harboring uncommon EGFR mutations

被引：0

作者：

Wang, Pingli ^{[1
]}

Cao, Liming ^{[2
]}

Tian, Panwen ^{[3
]}

Ren, Shengxiang ^{[4
]}

Miao, Liyun ^{[5
]}

Zhou, Chengzhi ^{[6
]}

Fan, Yun ^{[7
]}

Li, Yuping ^{[8
]}

Lv, Dongqing ^{[9
]}

Zhao, Xin ^{[10
]}

Yang, Mei ^{[11
]}

Zhu, Chaonan ^{[11
]}

Yu, Bing ^{[11
]}

Xu, June ^{[11
]}

Song, Yong ^{[12
]}

Wang, Kai ^{[1
,13
]}

机构：

[1] Zhejiang Univ, Dept Resp & Crit Care Med, Affiliated Hosp 2, Sch Med, Hangzhou 310009, Zhejiang, Peoples R China

[2] Cent South Univ, Xiangya Hosp, Dept Resp Med, Changsha, Hunan, Peoples R China

[3] Sichuan Univ, Dept Resp & Crit Care Med, West China Hosp, Chengdu, Sichuan, Peoples R China

[4] Shanghai Pulm Hosp, Dept Med Oncol, Shanghai, Peoples R China

[5] Nanjing Univ, Dept Resp Med, Drum Tower Hosp, Med Sch, Nanjing, Jiangsu, Peoples R China

[6] Guangzhou Med Univ, Dept Pulm & Crit Care Med, Affiliated Hosp 1, Guangzhou, Guangdong, Peoples R China

[7] Univ Chinese Acad Sci, Dept Med Thorac Oncol, Canc Hosp, Hangzhou, Zhejiang, Peoples R China

[8] Wenzhou Med Univ, Dept Pulm & Crit Care Med, Affiliated Hosp 1, Wenzhou, Zhejiang, Peoples R China

[9] Taizhou Hosp Zhejiang Prov, Dept Resp Med, Taizhou, Zhejiang, Peoples R China

[10] Nanjing Med Univ, Jiangsu Prov Hosp, Dept Resp & Crit Care Med, Affiliated Hosp 1, Nanjing, Jiangsu, Peoples R China

[11] Hangzhou ZhongMei HuaDong Pharmaceut Co, Huadong Global Dev Ctr, Hangzhou, Zhejiang, Peoples R China

[12] Gen Hosp Eastern Theater Command, Dept Resp Med, Nanjing 350025, Jiangsu, Peoples R China

[13] Zhejiang Univ, Dept Resp & Crit Care Med, Affiliated Hosp 4, Sch Med, Yiwu, Zhejiang, Peoples R China

来源：

CANCER COMMUNICATIONS | 2023年 / 43卷 / 09期

关键词：

AFATINIB;

D O I：

10.1002/cac2.12456

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

引用

页码：1059 / 1063

页数：5

共 50 条

[1] Mefatinib as first-line treatment of patients with advanced non-small cell lung cancer harboring rare EGFR mutations.
Wang, Pingli
Cao, Liming
Tian, Panwen
Ren, Shengxiang
Miao, Liyun
Zhou, Chengzhi
Fan, Yun
Li, Yuping
Lv, Dongqing
Zhao, Xin
Yang, Mei
Zhu, Chaonan
Xu, June
Song, Yong
Wang, Kai
JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
[2] Mefatinib as first-line treatment of patients with advanced EGFR-mutant non-small-cell lung cancer: a phase Ib/II efficacy and biomarker study
Wang, Pingli
Li, Yuping
Lv, Dongqing
Yang, Lingge
Ding, Liren
Zhou, Jianya
Hong, Wei
Chen, Youfei
Zhang, Dongqing
He, Susu
Zhou, Jianying
Wang, Kai
SIGNAL TRANSDUCTION AND TARGETED THERAPY, 2021, 6 (01)
[3] Mefatinib as first-line treatment of patients with advanced EGFR-mutant non-small-cell lung cancer: a phase Ib/II efficacy and biomarker study
Pingli Wang
Yuping Li
Dongqing Lv
Lingge Yang
Liren Ding
Jianya Zhou
Wei Hong
Youfei Chen
Dongqing Zhang
Susu He
Jianying Zhou
Kai Wang
Signal Transduction and Targeted Therapy, 6
[4] First-line gefitinib in patients with advanced non-small-cell lung cancer harboring somatic EGFR mutations
Sequist, Lecia V.
Martins, Renato G.
Spigel, David
Grunberg, Steven M.
Spira, Alexander
Jaenne, Pasi A.
Joshi, Victoria A.
McCollum, David
Evans, Tracey L.
Muzikansky, Alona
Kuhlmann, Georgiana L.
Han, Moon
Goldberg, Jonathan S.
Settleman, Jeffrey
Iafrate, A. John
Engelman, Jeffrey A.
Haber, Daniel A.
Johnson, Bruce E.
Lynch, Thomas J.
JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15) : 2442 - 2449
[5] Anlotinib with gefitinib as first-line therapy in advanced non-small cell lung cancer harboring EGFR mutations: A phase II study
Ji, Y.
Wang, X.
Lou, Z.
ANNALS OF ONCOLOGY, 2021, 32 : S979 - S979
[6] First-line Afatinib in Patients With Non-small-cell Lung Cancer With Uncommon EGFR Mutations in South Korea
Kim, Mi-Hyun
Choi, Chang Min
Lee, Sung Yong
Park, Cheol Kyu
Chang, Yoon Soo
Lee, Kye Young
Kim, Seung Joon
Yang, Sei Hoon
Ryu, Jeong Seon
Lee, Jeong Eun
Lee, Shin Yup
Park, Chan Kwon
Lee, Sang Hoon
Jang, Seung Hun
Yoon, Seong Hoon
Jang, Tae Won
ANTICANCER RESEARCH, 2022, 42 (03) : 1615 - 1622
[7] A phase II study of afatinib treatment for elderly patients with previously untreated advanced non-small-cell lung cancer harboring EGFR mutations
Imai, Hisao
Kaira, Kyoichi
Suzuki, Kensuke
Anzai, Masaki
Tsuda, Takeshi
Ishizuka, Tamotsu
Kuwako, Tomohito
Naruse, Ichiro
Nemoto, Kenji
Uchino, Junji
Morozumi, Nobutoshi
Ishihara, Shinichi
Minato, Koichi
Hisada, Takeshi
LUNG CANCER, 2018, 126 : 41 - 47
[8] TKI as First Line Treatment in Advanced Non-Small-Cell Lung Cancer with EGFR Mutations
Guerreiro, Ines
Silva, Ana Vitor
Rodrigues, Ana
Oliveira, Cristina
Pousa, Ines
Oliveira, Julio
JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (01) : S1244 - S1245
[9] First-line single agent treatment with gefitinib in patients with advanced non-small-cell lung cancer: A phase II study
Niho, S
Kubota, K
Goto, K
Yoh, K
Ohmatsu, H
Kakinuma, R
Saijo, N
Nishiwaki, Y
JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (01) : 64 - 69
[10] Osimertinib as first-line treatment of EGFR mutant advanced non-small-cell lung cancer
Liam, Chong-Kin
TRANSLATIONAL LUNG CANCER RESEARCH, 2017, 6 : S62 - S66

← 1 2 3 4 5 →